Phase 2/3RecruitingAge-related condition
A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-002) (MALBEC)
A Randomized Double-masked, Multicenter, 3-arm, Pivotal Phase 2/3 Study to Evaluate the Efficacy and Safety of Intravitreal (IVT) EYE201/MK-8748 Compared to Aflibercept (2 mg) in Participants With Neovascular Age-related Macular Degeneration (NVAMD)
- Sponsor
- EyeBiotech Ltd. (Industry)
- Enrolment
- 960 planned
- Conditions
- Macular Degeneration; Age-Related Macular Degeneration; Choroidal Neovascularization; Wet Macular Degeneration
- Interventions
- Tiespectus; Aflibercept
- Ages
- adults, older adults
- Registry
- NCT07440225
Full record on ClinicalTrials.gov
From the registry
Researchers are looking for new ways to treat neovascular age-related macular degeneration (NVAMD). Available standard (usual) treatments for NVAMD, such as aflibercept, may not work for every person. Researchers want to learn if a trial medicine called tiespectus (also called MK-8748 or EYE201) can treat NVAMD. The goal of this trial is to learn if tiespectus works as well as aflibercept to treat NVAMD.
Primary outcomes
- Mean Change in Best-Corrected Visual Acuity (BCVA) [Early Treatment of Diabetic Retinopathy Study (ETDRS Letters)] From Baseline to Year 1
History
Primary completion expected
Last registry update
Started
Registered